+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "MEDI8897"

U.S. Respiratory Syncytial Virus Vaccines Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Country: (U.S.) - Product Thumbnail Image

U.S. Respiratory Syncytial Virus Vaccines Market - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Country: (U.S.)

  • Report
  • September 2024
  • 304 Pages
  • United States
From
Global Respiratory Syncytial Virus Market Size and Epidemiology (8MM), By Drug Type (Synagis, Other), By Dosage Form (Oral, Other), By Treatment Type (Immune prophylaxis, Other), By Distribution Channel (Clinics, Other) -Estimation & Forecast - Product Thumbnail Image

Global Respiratory Syncytial Virus Market Size and Epidemiology (8MM), By Drug Type (Synagis, Other), By Dosage Form (Oral, Other), By Treatment Type (Immune prophylaxis, Other), By Distribution Channel (Clinics, Other) -Estimation & Forecast

  • Report
  • June 2021
  • 675 Pages
  • Global
From
MEDI8897 Market Size, Forecast, and Market Insight - 2032 - Product Thumbnail Image

MEDI8897 Market Size, Forecast, and Market Insight - 2032

  • Report
  • February 2024
  • 30 Pages
  • Global
From
  • 3 Results (Page 1 of 1)
Loading Indicator

The MEDI8897 market is a segment of the global vaccines market, focusing on the development and commercialization of a recombinant protein-based vaccine for the prevention of respiratory syncytial virus (RSV) infection. MEDI8897 is a monoclonal antibody-based vaccine that has been designed to target the RSV F protein, which is the primary target of the virus. The vaccine is intended to provide protection against RSV infection in infants and young children, as well as in adults. The MEDI8897 market is expected to grow in the coming years, as the demand for RSV vaccines increases. The development of the vaccine is being driven by the need to reduce the burden of RSV-related illnesses, which can cause severe respiratory illness in infants and young children. Companies in the MEDI8897 market include Novavax, GlaxoSmithKline, Merck, and Sanofi. These companies are actively involved in the development and commercialization of the vaccine, and are expected to be key players in the market in the coming years. Show Less Read more